Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2020 - 12 - 11 save search
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
Published: 2020-12-11 (Crawled : 21:06) - globenewswire.com
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
| Email alert
Add to watchlist
trial phase 3 phase 1 phase 2 solid tumors
Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
GERN | $3.57 2.0% 1.96% 6.6M
|
Health Technology
|
| O: 0.86%
H: 0.57%
C: -1.7%
phase 3 trial
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
Published: 2020-11-04 (Crawled : 14:47) - ir.vtvtherapeutics.com
VTVT | $25.39 1.66% 1.63% 4.2K
|
Health Technology
|
| O: -10.11%
H: 12.5%
C: 7.5%
diabetes phase 3 enroll
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
Published: 2019-05-01 (Crawled : 11:51) - globenewswire.com
XERS | $1.765 -0.84% -0.85% 710K
|
Health Technology
| Email alert
Add to watchlist
results phase 3 phase 1 phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.